Metoclopramide increases the bioavailability of dantrolene in spinal cord injury

Journal of Clinical Pharmacology

Volumn 36, Issue 1, 1996, Pages 64-71

  Gilman, Thomas M ^a   Segal, Jack L ^b,c   Brunnemann, Sherry R ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DANTROLENE; METOCLOPRAMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG MIXTURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALIGNANT HYPERTHERMIA; MOTOR NEURON DISEASE; ORAL DRUG ADMINISTRATION; PARALYSIS; QUADRIPLEGIA; SPASTICITY; SPINAL CORD INJURY;

EID: 0030038822     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04153.x     Document Type: Article

References (34)

1. Ellis KO, White RL, Wright GC, Wessels FL: Synthesis and skeletal muscle relaxant activity of quaternary ammonium salts of dantrolene and clodanolene. J Pharm Sci 1980;69:327-331.
2. Pinder RM, Brogden RN, Speight TM, Avery GS: Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity. Drugs 1977;13:3-23.
3. Ward A, Chaffman MO, Sorkin EM: Dantrolene: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs 1986; 32: 130-168.
4. Utili R, Boitnott JK, Zimmerman HJ: Dantrolene associated hepatic injury: incidence and character. Gastroenterology 1977;72: 610-617.
5. Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS: Metoclopramide: a review of its pharmacolgical properties and clinical use. Drugs 1976;12:81-131.
6. Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romankiewicz JA, Heel RC: Metoclopramide: an updated review of its pharmacological properties and clinical use. Drugs 1983; 25: 451-494.
7. Segal JL, Milne N, Brunnemann SR: Gastric emptying is impaired in patients with spinal cord injury. Am J Gastroenterol 1995;90:466-470.
8. Nino-Murcia M, Friedland GW: Functional abnormalities of the gastrointestinal tract in patients with spinal cord injuries: evaluation with imaging procedures. AJR Am J Roentgenol 1992;158:279-281.
9. Halstead LS, Feldman S, Claus-Walker J, Patel VC: Drug absorption in spinal cord injury. Arch Phys Med Rehabil 1985;66:298-301.
10. Segal JL, Milne N, Brunnemann SR, Lyons KP: Metoclopramide-induced normalization of impaired gastric emptying in spinal cord injury. Am J Gastroenterol 1987;82:1143-1148.
11. Metropolitan Life Insurance Company: New weight standard for men and women. Stat Bull Metrop Insurance Co 1959:40:3-6.
12. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
13. Mirahmadi MK, Byrne C, Barton C, Penera N, Gordon S, Vaziri ND: Prediction of creatinine clearance from serum creatinine in spinal cord injury patients. Paraplegia 1983; 21:23-29.
14. Hackett LP, Dusci LJ: Determination of dantrolene sodium in human plasma using high-performance liquid chromatography. J Chromatogr 1979;79:222-224.
15. Wuis EW, Grutiers ACLM, Grutiers, Vree TB, Van Der Kleyn E: Simultaneous determination of dantrolene and its metabolites, 5-hydroxydantrolene and nitro-reduced acetylated dantrolene (F 490), in plasma and urine of man and dog by high-performance liquid chromatography. J Chromatogr 1982;231:401-409.
16. SAS Institute: The NESTED Procedure. In, SAS/STAT Guide for Personal Computers. Version 6. Gary, NC: SAS Institute, 1987:667-674.
17. Purves RD: Optimum numerical integration methods for estimation of area under the curve and area under the moment curve. J Pharmacokinet Biopharm 1992;20:211-226.
18. Gibaldi M, Perrier D: Pharmacokinetics. Second edition. New York: Marcel, Inc., 1982.
19. Veng Pedersen P: Mean time parameters in pharmacokinetics. II. Definition, computation, and clinical implications. Clin Pharmacokinet 1989;17:424-440.
20. Zar JH: Two-sample hypothesis. In, Biostatistical Analysis. Second edition. Englewood Cliffs, NJ: Prentice-Hall, 1984;138-141.
21. SAS Institute: The NPAR1WAY procedure. In, SAS/STAT Guide for Personal Computers. Version 6. Cary, NC: SAS Institute, 1987:713-726.
22. Zar JH: Paired-sample hypothesis. In, Biostatistical Analysis. Second edition. Englewood Cliffs, NJ: Prentice-Hall, 1984;153-155.
23. SAS Institute: The UNIVARIATE Procedure. SAS User's Guide: Basics. Version 5. Cary, NC: SAS Institute, 1985; 1181-1191.
24. Shapiro SS, Wilk MB: An analysis of variance test for normality (complete samples). Biometrika 1965;52:591-611.
25. Inotsume N, Nakano M: Hydrolytic behaviour of dantrolene in acidic media at body temperature. Int J Pharm 1983;17:357-360.
26. Albibi R, McCallum RW: Metoclopramide: pharmacology and clinical application. Ann Intern Med 1983;98:86-95.
27. Van Wyk M, Sommers DK, Moncrieff J: Effects of enhancement and antagonism of 5-hydroxy-tryptamine activity on the influence of metoclopramide on gastric emptying. Digestion 1993:54:40-43
28. Greiff JMC, Rowbotham D: Pharmacokinetic drug interactions with gastrointestinal motility modifying agents. Clin Pharmacokinet 1994;27:447-461.
29. Nimmo J, Heading RC, Tothill P, Prescott LF: Pharmacological modification of gastric emptying: effects of propantheline and metoclopromide on paracetamol absorption. Br Med J 1973; 1: 587-589.
30. Manninen V, Apajalahti A, Melin J, Karesoja M: Altered absorption of digoxin in patients given propantheline and metoclopramide. Lancet 1973;1:398-400.
31. Gibaldi M: Gastrointestinal absorption: physicochemical considerations. In, Biopharmaceutics and Clinical Pharmacokinetics. Fourth edition. Philadelphia: Lea and Febiger, 1991:40-60.
32. Poelma FGJ, Tukker JJ, Crommelin DJA: Intestinal absorption of drugs I: the influence of taurocholate on the absorption of dantrolene in the small intestine of the rat. J Pharm Sci 1989;78:285-289.
33. Meyler WJ, Bakker H, Kok JJ, Agoston S, Wesseling H: The effect of dantrolene sodium in relation to blood levels in spastic patients after prolonged adminsitration. J Neurol Neurosurg Psychiatr 1981;44:334-339.
34. Vallner JJ, Honigberg IL, Stewart JT, Peyton AB: Dantrolene and metabolite levels in six patients on chronic therapy. Curr Ther Res 1979;25:79-91.